araag2/HINT huggingface dataset:
Clinical trial NCT01095016 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: meptin swinghaler, berotec
SMILES: CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or females outpatients aged ≥18 years old with uncontrolled or partly controlled
             asthma; Stability was assessed during the past 14 days the patients remained in the
             same severity class by 2006 GINA guideline (uncontrolled, partly controlled) and had
             no acute exacerbations by investigator judgment;

          -  Pulmonary function test: Improvement ≥12% reversibility in FEV1 or FVC following
             administration of an inhaled β2-agonist before the study or ; Positive result of
             Brocho-provocation test;

        Exclusion Criteria:

          -  Hypersensitivity to β2-agonist or lactose;

          -  Hospitalization due to asthma during the previous 3 months;

          -  Respiratory tract infection requiring treatment with antibiotics in the previous 4
             weeks;

          -  Oral or systemic corticosteroids in the previous 4 weeks;

          -  Inadequately controlled hyperthyroidism;

          -  Subjects with any clinically significant disorder of the cardiovascular, neurologic,
             hematologic, gastrointestinal, cerebrovascular, or immunologic system or respiratory
             disease other than asthma(e.g. COPD), or any other disorder which may interfere wth
             the study evaluations or affect subject safety;

          -  Patients receive an investigational drug within 30 days prior to admission to the
             study;

          -  Patients with significant alcohol, drug or medication abuse as judged by the
             investigator;

          -  Females who are pregnant or breast-feeding; (exception: Females of child-bearing age
             might be included, if in the opinion of the investigator, they are using adequate
             contraceptive precautions);

          -  Subjects who are heavy smoker (more than 10 packs year) or who are smoking within
             previous 6 months.
Clinical trial NCT01851330 (phase 3, status: completed)
Conditions: chronic hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18, with chronic genotype 1 HCV infection

          -  HCV treatment-naive

          -  HCV RNA > 10,000 IU/mL at screening

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Presence of cirrhosis

          -  Coinfection with HIV or hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
Clinical trial NCT01468038 (phase 3, status: completed)
Conditions: sleep disorder
ICD codes: G47.9, G47.21, G47.22, G47.23, G47.52, G47.29, G47.20
Drugs: trazodone, sentra pm and trazodone (copack kit trazamine), placebo trazodone and placebo sentra pm
SMILES: ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1, ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females over the age of 18 and below age 65.

          -  Patients with a history of a sleep disturbance with non-restorative sleep defined by
             perceived increase in sleep latency or morning/daytime grogginess.

        Exclusion Criteria:

          -  Subjects who have previously taken GABAdone, SentraPM or trazadone.

          -  Subjects who are currently taking tricyclic anti-depressants.

          -  Any blood chemistry anomalies the investigator finds that may put the patient at risk
             or invalidate study results.

          -  Pregnant or lactating females.

          -  Subjects with implanted pacemakers or other implanted electrical devices
Clinical trial NCT00056277 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: lamotrigine
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must provide written and informed consent

          -  Diagnosis of Bipolar I Disorder and currently depressed for minimum of the previous 8
             weeks

          -  Patients must have been hospitalized for mood disorder or incarceration with or
             without formal charges as the result of mania related behavior

        Exclusion Criteria:

          -  Patients must not be suicidal

          -  Patients must not have a history or non-response to antidepressant treatment

          -  Patients must not have a clinical history of substance dependence in the past year or
             abuse within the 4 weeks prior to study entry

          -  Patients must not have had epilepsy or hypothyroidism
Clinical trial NCT00689104 (phase 3, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: mirabegron, tolterodine, placebo to mirabegron, placebo to tolterodine
SMILES: NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is willing and able to complete the micturition diary and questionnaires
             correctly

          -  Subject has symptoms of overactive bladder (urinary frequency and urgency with or
             without urge incontinence) for ≥ 3 months

          -  Subject experiences frequency of micturition on average ≥ 8 times per 24-hour period
             during the 3-day micturition diary period

          -  Subject must experience at least 3 episodes of urgency (grade 3 or 4) with or without
             incontinence, during the 3-day micturition diary period

        Exclusion Criteria:

          -  Subject is breastfeeding, pregnant, intends to become pregnant during the study, or of
             childbearing potential, sexually active and not practicing a highly reliable method of
             birth control

          -  Subject has significant stress incontinence or mixed stress/urge incontinence where
             stress is the predominant factor

          -  Subject has an indwelling catheter or practices intermittent self-catheterization

          -  Subject has diabetic neuropathy

          -  Subject has evidence of a symptomatic urinary tract infection, chronic inflammation
             such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or
             previous or current malignant disease of the pelvic organs

          -  Subject receives non-drug treatment including electro-stimulation therapy

          -  Subject has severe hypertension

          -  Subject has a known or suspected hypersensitivity to tolterodine, other
             anticholinergics, YM178, other beta-adrenoreceptor (ß-AR) agonists, or lactose or any
             of the other inactive ingredients

          -  Subject has been treated with any investigational drug or device within 30 days (90
             days in the UK)

          -  Subject had an average total daily urine volume > 3000 mL as recorded in the 3-day
             micturition diary period

          -  Subject has serum creatinine >150 umol/L, aspartate aminotransferase (AST) and/or
             alanine aminotransferase (ALT) > 2x upper limit of normal range (ULN), or gamma
             glutamyl transferase (γ-GT) > 3x ULN

          -  Subject has a clinically significant abnormal electrocardiogram (ECG)
Clinical trial NCT00395746 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sulfonylurea, liraglutide, liraglutide
SMILES: [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Diet/exercise therapy with sulfonylurea (SU) for at least eight weeks

          -  HbA1c greater than or equal to 7.0% and less than 10.0%

          -  BMI less than 35 kg/m2

        Exclusion Criteria:

          -  Treatment with insulin within the last 12 weeks

          -  Treatment with any drug that could interfere with the glucose level

          -  Any serious medical condition

          -  Females who are pregnant, have intention of becoming pregnant or are breastfeeding
Clinical trial NCT00086593 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: lamotrigine
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosed with schizophrenia.

          -  Exhibits persistent positive symptoms that have persisted for a minimum of 3 months
             prior to screening.

          -  Continuously taking 1-2 specific atypical antipsychotics for a minimum of 3 months and
             must be on a stable dose for at least 1 month prior to entering the study.

          -  Participant or a legal guardian is able to understand and sign the consent form.

        Exclusion criteria:

          -  PANSS (Positive and Negative Syndrome Score) total score increases or decreases by
             more than 20% between the Screening and Baseline visits.

          -  Predominant Axis I disorder other than schizophrenia within 6 months prior to
             screening.

          -  History of clinically significant or unstable medical disorder or treatment that would
             interfere with the study.

          -  History of autistic disorder or another pervasive developmental disorder, organic
             brain disease, dementia, stroke, epilepsy or a history of seizures requiring treatment
             (this does not include febrile seizures as a child), or those who have suffered a
             traumatic head injury.

          -  Taking psychotropic or primarily centrally active medication at screening.

          -  Use of antidepressant medications or mood stabilizers within 1 month of screening.
Clinical trial NCT00571168 (phase 3, status: unknown status)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: emend, placebo
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women >/= 18 years

          -  Patients with multiple myeloma receiving high-dose chemotherapy (Melphalan) and
             autologous peripheral stemcell transplantation

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients suffering from nausea and vomiting during the last 12 hours prior to planned
             high-dose chemotherapy

          -  Patients receiving antiemetics 24 hours prior to planned high-dose chemotherapy

          -  Intake of steroids

          -  History of hypersensitivity to the investigational product or to any drug with similar
             chemical structure or to any excipient present in the pharmaceutical form of the
             investigational product

          -  Simultaneous intake of pimozide, terfenadine, astemizole

          -  Pregnant or nursing woman

          -  Mental condition rendering the subject incapable to understand the nature, scope and
             possible consequences of the trial

          -  Expected non-compliance in completing the subject´s diary and FLIE-score
Clinical trial NCT01110889 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: agomelatine (ago178c), agomelatine (ago178c), placebo
SMILES: COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1, COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with diagnosis of MDD, single or recurrent episode, according to DSM-IV
             criteria.

          -  Current episode ≥4 weeks.

          -  CGI-Severity score ≥4 at Screening and Baseline.

        Exclusion Criteria:

          -  History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating
             disorder (current or during previous one year), obsessive-compulsive disorder.

          -  Any other current Axis I disorder other than MDD which is the focus of treatment.

          -  Substance or alcohol abuse in the last 30 days, dependence in the last 6 months.

          -  Concomitant psychotropic medication, including herbal preparations and melatonin.

          -  Psychotherapy of any type.

          -  Prior exposure to agomelatine.

          -  Female patients of childbearing potential who are not using effective contraception.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00099502 (phase 3, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: interferon beta-1b (betaferon/betaseron, bay86-5046), interferon beta-1b (betaferon/betaseron, bay86-5046), copaxone
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Female and male patients

          -  Aged 18-55 years

          -  Diagnosis of RRMS (Relapsing-Remitting Multiple Sclerosis), EDSS score of 0 to 5.0

          -  Treatment-naive to IFNB or Copaxone

        Exclusion Criteria:

          -  Neurological progression at disease onset or between relapses

          -  Serious or acute heart diseases

          -  History of severe depression or suicide attempt

          -  Serious or acute liver, renal or bone marrow dysfunction

          -  Monoclonal gammopathy

          -  Known allergy to Gadolinium-DTPA, to IFNs (Interferons), to glatiramer acetate, to
             human albumin or to mannitol

          -  Pregnancy or lactation
Clinical trial NCT00153777 (phase 3, status: terminated)
Conditions: hiv infection
ICD codes: Z21
Drugs: cellulose sulfate gel (6%)
SMILES: OC(=O)CC(O)(CC(O)=O)C(O)=O
Reason stopped: 
    idmc recommendation
  
Eligibility criteria:

        Inclusion Criteria:

          -  at least 18 years old

          -  an average of at least three vaginal sex acts per week, at least three different
             partners in the last three months, expecting to continue this behavior

          -  HIV negative

          -  willing and able to comply with the protocol

        Exclusion Criteria:

          -  pregnancy

          -  allergy to latex or spermicides

          -  intravenous drug user
Clinical trial NCT00276094 (phase 3, status: completed)
Conditions: atrophy, vaginal diseases
ICD codes: H21.29, H31.23, H47.20, H47.22, N50.0, N64.2, N90.5
Drugs: ospemifene 30 mg, ospemifene 60 mg, placebo, nonhormonal vaginal lubricant
SMILES: OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1, OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Naturally or surgically postmenopausal

          -  Moderate or severe symptoms of vaginal atrophy (ie, vaginal dryness, irritation or
             itching, difficult or painful urination, pain or bleeding with intercourse)

          -  Vaginal pH greater than 5.0

          -  5% or fewer superficial cells in maturation index of vaginal smear

        Exclusion Criteria:

          -  Evidence of endometrial hyperplasia, endometrial cancer, or other abnormal endometrial
             pathology

          -  Abnormal Pap smear

          -  Uterine bleeding of unknown origin or uterine polyps

          -  Current vaginal infection requiring medication
Clinical trial NCT00613938 (phase 3, status: completed)
Conditions: arthralgia, bunion, hallux valgus, pain
ICD codes: M26.621, M26.622, M26.623, M26.629, M21.611, M21.612, M21.619, M21.621, M21.622, M21.629, M20.10, M20.11, M20.12, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: tapentadol (cg5503), tapentadol (cg5503), oxycodone, placebo
SMILES: CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must undergo primary unilateral first metatarsal bunionectomy

          -  Pain intensity must be moderate to severe following removal of a continuous popliteal
             sciatic block

          -  Female patients must be postmenopausal, surgically sterile, or practicing an effective
             method of birth control if they are sexually active.

        Exclusion Criteria:

          -  Patients will be excluded from the study if they have a history of seizure disorder or
             epilepsy

          -  History of malignancy within the past 2 years before starting the study

          -  History of alcohol or drug abuse

          -  Evidence of active infections that may spread to other areas of the body

          -  Clinical laboratory values reflecting severe renal insufficiency

          -  Moderately or severely impaired hepatic function

          -  Currently treated with anticonvulsants, monoamine oxidase inhibitors (MAOIs),
             tricyclic antidepressants (TCAs), neuroleptics, or serotonin norepinephrine reuptake
             inhibitor (SNRI).
Clinical trial NCT00633880 (phase 3, status: completed)
Conditions: symptomatic neurogenic orthostatic hypotension (noh), non-diabetic neuropathy, primary autonomic failure, dopamine beta hydroxylase deficiency
ICD codes: D72.820, D72.821, A52.10, A52.19, E28.310, A52.79, E89.41, H35.23, H35.20, H35.21, H35.22, G90.4, G90.09, G44.091, G90.8, G99.0, G44.099, G90.9, D81.810, E53.0, E53.1, E61.0, E61.1, E61.2, E61.3
Drugs: placebo, droxidopa
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O
Eligibility criteria:

        PATIENT INCLUSION CRITERIA:

          -  Male or female and aged 18 years or over;

          -  Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic
             Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency or Non-Diabetic
             Autonomic Neuropathies;

          -  A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic
             blood pressure of at least 10 mmHg, within 3 minutes after standing;

          -  Provide written informed consent to participate in the study and understand that they
             may withdraw their consent at any time without prejudice to their future medical care.

        MAIN PATIENT EXCLUSION CRITERIA:

          -  Taking ephedrine or midodrine; Patients taking ephedrine or midodrine may enroll after
             a minimum 7 day washout period;

          -  Taking anti-hypertensive medication;

          -  Have a history of more than moderate alcohol consumption;

          -  Women who are pregnant or lactating;

          -  Have a history of closed angle glaucoma;

          -  Have pre-existing sustained severe hypertension (BP > 180/110 mmHg in the sitting
             position);

          -  Have atrial fibrillation or, in the investigator's opinion, have any other significant
             cardiac arrhythmia;

          -  In the investigator's opinion, have any other significant systemic, hepatic, cardiac
             or renal illness;

          -  Have diabetes mellitus or insipidus;

          -  Have a known or suspected malignancy;

          -  Have known gastrointestinal illness or other gastrointestinal disorder that may, in
             the investigator's opinion, affect the absorption of study drug;

          -  In the investigator's opinion, have clinically significant abnormalities on clinical
             examination or laboratory testing;

          -  Have a serum creatinine level > 130 µmol/L;
Clinical trial NCT01185223 (phase 3, status: terminated)
Conditions: allogeneic stem cell transplantation
ICD codes: M31.11
Drugs: valganciclovir, ganciclovir
SMILES: CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O, NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient following allogeneic SCT

          -  Patient with a first episode of positive CMV-PCR (DNAemia) or pp65 antigenemia assay
             (antigenemia) up to 100 days after SCT

          -  Absolute neutrophil count (ANC) ≥1000 cells/µL on 2 consecutive follow-ups within 10
             days before randomization

          -  Patient has a creatinine clearance of ≥25 mL/min (calculated by the Cockcroft-Gault
             formula, see Part I Section 6.1.2) with evidence of improving renal function,

          -  None or gastrointestinal graft-versus-host disease (GVHD) up to grade 2

        Exclusion Criteria:

          -  Patient has a suspected or diagnosed CMV disease

          -  Patient has received syngeneic SCT

          -  Patient who received an investigational medicinal product (IMP) within the last 30
             days prior to screening or who is simultaneously participating in another clinical
             study with an IMP

          -  Patient with a body weight <50 kg or >95 kg,

          -  Patient has received anti-CMV therapy within the past 30 days prior to screening (the
             use of acyclovir, valacyclovir, or famciclovir is permitted)

          -  Patient who has participated in this study before,

          -  Patient who shows a neutropenia, thrombocytopenia, or anemia within 10 days before or
             at the time point of randomization as following:

               -  The ANC is <1000 cells/μL on 2 consecutive follow-ups, or

               -  A platelet count of ≥25000/μL can not be achieved/maintained with platelet
                  transfusions

               -  A hemoglobin level of ≥8g/dL can not be achieved/maintained by red blood cell
                  transfusions